Oppenheimer Upgrades Incyte on Growth Beyond Jakafi’s 2029 Loss of Exclusivity

Enna Lee

1 min read

Add as a preferred source on Google

Oppenheimer Upgrades Incyte on Growth Beyond Jakafi’s 2029 Loss of Exclusivity

The firm set a $144 price target, about 23% above Incyte’s Oct. 29 close.

By Enna Lee

Published Oct 30, 2026, 1:17 PM EDT

An amber medicine vial and tablet sit on rising blocks / TokenPost.ai

Oppenheimer upgraded Incyte to Outperform from Market Perform, citing growth prospects beyond Jakafi’s loss of exclusivity in 2029. Jakafi is ruxolitinib.

The firm set a $144 price target, about 23% above Incyte’s Oct. 29 closing price.

Enna Lee

Reporter

Enna Lee reports on investing and digital-asset markets for TokenPost. Send corrections or tips to info@tokenpost.com.